Mar 26, 2024 | Commentary
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
Dec 7, 2023 | Commentary
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
Nov 2, 2023 | Commentary
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Sep 26, 2023 | Commentary
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
Jul 19, 2023 | Interviews
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.